Thalidomide for Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Multiple Myeloma
Interventions
DRUG

Thalidomide

200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)

Trial Locations (1)

77030

University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER